molecules of the month


selective TGFβR1 kinase inhibitor

completed oral CV studies in higher species

from data mining of internal matter and opt.

ACS Med. Chem. Lett. 11, 172-178

Bristol-Myers Squibb, Princeton, NJ

1 min read

BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: